top of page
Multiple Myeoma Clinical Trials Currently Recruiting
2021 - (R) NCT04827563
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
2020 - (R) NCT04634552
Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
2020 - (R) NCT04394650
Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
2020 - (R) NCT04318327
Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
2020 - (R) NCT04244656
Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
2019 - (R) NCT04184050
Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
2019 - (R) NCT04155749
Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
2019 - (R) NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2016 - (R) NCT02899052
Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
2016 - (R) NCT02884102
MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
2016 - (R) NCT02675452
Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
2014 - (R) NCT02199665
Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
2012 - (R) NCT01665794
Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM